US Stock Insider Trading | Wave Life Sciences Discloses 4 Insider Transactions on February 11

2026-02-25 05:45:08

On February 11, 2026, Wave Life Sciences (WVE) disclosed four insider trading transactions. Director BOLNO PAUL sold 10,500 shares on February 9, 2026.

【Recent Insider Transactions】

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
February 11, 2026	Executive	Moran Kyle	February 9, 2026	Sell	3,588	13.45	$48,300
February 11, 2026	Executive	Francis Chris	February 9, 2026	Sell	1,883	13.45	$23,300
February 11, 2026	Director	BOLNO PAUL	February 9, 2026	Sell	10,500	13.45	$141,000
February 11, 2026	Executive	Vargeese Chandra	February 9, 2026	Sell	3,228	13.45	$43,400
January 6, 2026	Executive	Francis Chris	January 2, 2026	Sell	1,295	16.70	$21,600
January 6, 2026	Executive	Francis Chris	January 2, 2026	Sell	8,080	15.92	$128,600
January 6, 2026	Executive	Francis Chris	January 2, 2026	Buy	9,375	3.14	$29,400
December 15, 2025	Shareholder holding over 10%	GSK plc	December 11, 2025	Buy	1,470,000	19.00	$27,930,000
December 10, 2025	Director	HENRY CHRISTIAN O, Rawcliffe Adrian, Tan Aik Na, Wagner Heidi L	December 8, 2025	Buy	119,000	5.97	$7,104
December 10, 2025	Director	Tan Aik Na	December 8, 2025	Buy	32,200	5.37	$17,300

【Company Profile】

Wave Life Sciences Ltd. was incorporated in Singapore on July 23, 2012.

The company is a clinical-stage biotechnology firm focused on the broad potential of RNA therapeutics (also known as oligonucleotides) or targeted ribonucleic acid (“RNA”) to transform human health. The company’s RNA drug platform, PRISM™, combines multiple modalities, chemical innovations, and deep insights into human genetics to deliver scientific breakthroughs for treating rare and prevalent diseases. The company’s RNA targeting toolkit includes RNA editing, splicing, antisense silencing, and RNA interference (“RNAi”), providing unique capabilities for designing and sustainably delivering optimal candidates to address disease biology. The company’s lead projects involve rare and common diseases, including alpha-1 antitrypsin deficiency (“AATD”), obesity, Duchenne muscular dystrophy (“DMD”), and Huntington’s disease (“HD”).

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.